This is a special access protocol that will allow physicians access to aprotinin during the
temporary marketing suspension. The program will provide aprotinin for treatment of surgical
patients undergoing coronary artery bypass graft (CABG) surgery requiring cardiopulmonary
bypass (CPB) who are at increased risk of bleeding and transfusion when, in the opinion of
the treating physician, the patients require it, there is no acceptable alternative therapy,
and when there is a clearly favorable benefit-risk for the drug in that individual patient.